Human papillomavirus 9-valent recombinant vaccine

Adult: ≤45 years In women, for prevention of cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers caused by HPV types 16, 18, 31, 33, 45, 52 and 58; genital warts caused by HPV types 6 and 11; and precancerous or dysplastic lesions caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 (grades 1 and 2/3 cervical intraepithelial neoplasia; cervical adenocarcinoma in situ; grades 2 and 3 vulvar intraepithelial neoplasia; grades 2 and 3 vaginal intraepithelial neoplasia; grades 1, 2 and 3 anal intraepithelial neoplasia); in men, for prevention of anal, oropharyngeal and other head and neck cancers caused by HPV types 16, 18, 31, 33, 45, 52 and 58; genital warts caused by HPV types 6 and 11; and precancerous or dysplastic lesions caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 (grades 1, 2 and 3 anal intraepithelial neoplasia): As 3-dose schedule: 0.5 mL for 3 doses given at 0, 2 and 6 months via IM inj in the deltoid area of the upper arm or higher anterolateral area of the thigh. The 2nd dose may be given at least 1 month following the 1st dose and the 3rd dose at least 3 months after the 2nd dose. All 3 doses should be administered within 1 year. Recommendations may vary between countries; use must be in accordance with the local official guidelines.
Child: In girls and boys: 9-14 years As 2-dose schedule: 0.5 mL for 2 doses given at 0 and 6-12 months (administer a 3rd dose if the 2nd dose is given earlier than 5 months after the 1st dose); As 3-dose schedule: Same as adult dose. ≥15 years As 3-dose schedule: Same as adult dose. Doses are given via IM inj in the deltoid area of the upper arm or higher anterolateral area of the thigh. Recommendations may vary between countries; use must be in accordance with the local official guidelines.